Antibiotics in the clinical pipeline in 2013. (Q38133967)

29 August 2017

Antibiotics in the clinical pipeline in 2013. (English)

1 reference

29 August 2017

Mark S Butler

1

0 references

Mark Blaskovich

object named as

Mark A Blaskovich

series ordinal

2

0 references

Matthew A. Cooper

object named as

Matthew A Cooper

series ordinal

3

0 references

publication date

4 September 2013

1 reference

The Journal of Antibiotics

29 August 2017

1 reference

29 August 2017

66

1 reference

29 August 2017

571-591

1 reference

29 August 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1038/ja.2013.86

29 August 2017

0 references

cites work

Antibiotics in the clinical pipeline in 2011.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Thoughts and facts about antibiotics: where we are now and where we are heading

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Preserving the lifesaving power of antimicrobial agents

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Emergence of antibiotic resistance: need for a new paradigm

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Evolution of antibiotic resistance at non-lethal drug concentrations

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

The role of the natural environment in the emergence of antibiotic resistance in gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Antibiotics and antibiotic resistance: a bitter fight against evolution.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

35 years of resistance

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Fix the antibiotics pipeline.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Antibacterial R&D incentives

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

The critical impact of time discounting on economic incentives to overcome the antibiotic market failure

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Towards new business models for R&D for novel antibiotics.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Challenges in anti-infective development in the era of bad bugs, no drugs: a regulatory perspective using the example of bloodstream infection as an indication

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Physicochemical properties of antibacterial compounds: implications for drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Are natural products still the best source for antibacterial discovery? The bacterial entry factor.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Challenges of antibacterial discovery

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Drugs for bad bugs: confronting the challenges of antibacterial discovery

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Cost-Effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Recent derivatives from smaller classes of fermentation-derived antibacterials

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Overcoming the challenges to developing new antibiotics

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

New classes of antibiotics

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

New horizons for host defense peptides and lantibiotics

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Improving known classes of antibiotics: an optimistic approach for the future

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Antibiotics in development targeting protein synthesis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Tiacumicins, a novel complex of 18-membered macrolides. II. Isolation and structure determination

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Lipiarmycin, a new antibiotic from Actinoplanes. II. Isolation, chemical, bilogical and biochemical characterization.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Lipiarmycin, a new antibiotic from Actinoplanes. I. Description of the producer strain and fermentation studies.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Lipiarmycin, a new antibiotic from Actinoplanes III. Mechanism of action

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Structure elucidation of the macrocyclic antibiotic lipiarmycin

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Structure and biological activity of lipiarmycin B

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Clostomicins, new antibiotics produced by Micromonospora echinospora subsp. armeniaca subsp. nov. I. Production, isolation, and physico-chemical and biological properties

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

The transcription inhibitor lipiarmycin blocks DNA fitting into the RNA polymerase catalytic site

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Solithromycin inhibition of protein synthesis and ribosome biogenesis in Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Resolving biofilm infections: current therapy and drug discovery strategies.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Public-private partnership tackles TB challenges in parallel

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Diarylquinolines target subunit c of mycobacterial ATP synthase

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Amides of de-acetylglucosaminyl-deoxy teicoplanin active against highly glycopeptide-resistant enterococci. Synthesis and antibacterial activity

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Deacylation of the glycopeptide antibiotic A40926 by Actinoplanes teichomyceticus ATCC 31121

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Origin, structure, and activity in vitro and in vivo of dalbavancin

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatm

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009).

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Tedizolid (TR-701): a new oxazolidinone with enhanced potency

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

The oxazolidinones: past, present, and future.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Delamanid for multidrug-resistant pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Antitubercular activity in vivo of nicotinaldehyde thiosemicarbazone and its isomers

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Head-to-Head Prenyl Tranferases: Anti-Infective Drug Targets

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Quinolones: action and resistance updated

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Urinary pharmacokinetics and bactericidal activity of finafloxacin (200 and 800 mg) in healthy volunteers receiving a single oral dose

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Comparative in vitro activities of the novel antibacterial finafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Effect of pH on the in vitro activity of and propensity for emergence of resistance to fluoroquinolones, macrolides, and a ketolide.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to nemonoxacin, tigecycline, fosfomycin and other antimicrobial agents

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Naturally-occurring beta-lactamase inhibitors with antibacterial activity

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Clavulanic acid, a novel β-lactam isolated from Streptomyces clavuligerus; X-ray crystal structure analysis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

New β-lactam-β-lactamase inhibitor combinations in clinical development

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Discovery of LFF571: an investigational agent for Clostridium difficile infection

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Stieglitz rearrangement of N,N-dichloro-beta,beta-disubstituted taurines under mild aqueous conditions

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Quaternary ammonium N,N-dichloroamines as topical, antimicrobial agents

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

N-chloramines, a promising class of well-tolerated topical anti-infectives

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Are pleuromutilin antibiotics finally fit for human use?

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Synthesis and spectrum of the neoglycoside ACHN-490

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

ANTIBIOTIC 6640, A NEW MICROMONOSPORA-PRODUCBD AMINOGLYCOSIDE ANTIBIOTIC

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

The structure of sisomicin, a novel unsaturated aminocyclitol antibiotic from Micromonospora inyoensis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Activity of ACHN-490 against meticillin-resistant Staphylococcus aureus (MRSA) isolates from patients in US hospitals

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Peptide deformylase as an antibacterial target: a critical assessment

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Comparative in vitro activities of investigational peptide deformylase inhibitor NVP LBM-415 and other agents against human mycoplasmas and ureaplasmas

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Actinonin: an Antibiotic Substance produced by an Actinomycete

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Studies concerning the antibiotic actinonin. Part I. The constitution of actinonin. A natural hydroxamic acid with antibiotic activity

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

De novo design of antimicrobial polymers, foldamers, and small molecules: from discovery to practical applications

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Antimicrobial activities of twenty lysine-peptoid hybrids against clinically relevant bacteria and fungi.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Peptides as the next generation of anti-infectives.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Domain 5 of high molecular weight kininogen is antibacterial

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

A comprehensive summary of LL-37, the factotum human cathelicidin peptide.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Antimicrobial activities of LL-37 and its truncated variants against Burkholderia thailandensis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Mode of action of the antimicrobial peptide indolicidin.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

An anti-infective peptide that selectively modulates the innate immune response.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Sequestosome-1/p62 is the key intracellular target of innate defense regulator peptide

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Modulating immunity as a therapy for bacterial infections

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

The mechanism of action of PA-824: Novel insights from transcriptional profiling

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Recent development of potent analogues of oxazolidinone antibacterial agents

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Design at the atomic level: generation of novel hybrid biaryloxazolidinones as promising new antibiotics

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

New classes of antibacterial oxazolidinones with C-5, methylene O-Linked heterocyclic side chains

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Mode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Discovery of a novel and potent class of FabI-directed antibacterial agents

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Solid state of CG-400549, a novel FabI inhibitor: characterization, dissolution, transformation

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Triclosan: a widely used biocide and its link to antibiotics

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Activity of the new quinolones WCK 771, WCK 1152 and WCK 1153 against clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010-2011.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

A concise synthesis of a β-lactamase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Two decades of imipenem therapy

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Involvement of Fe uptake systems and AmpC β-lactamase in susceptibility to the siderophore monosulfactam BAL30072 in Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro activity of BAL30072 against Burkholderia pseudomallei

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Photodynamic effects of novel XF porphyrin derivatives on prokaryotic and eukaryotic cells

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial species

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Fungicidal photodynamic effect of a twofold positively charged porphyrin against Candida albicans planktonic cells and biofilms

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Organization of the biosynthetic genes encoding deoxyactagardine B (DAB), a new lantibiotic produced by Actinoplanes liguriae NCIMB41362.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Antimicrobial mechanism of lantibiotics

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

In vitro and in vivo activities of LCB01-0371, a new oxazolidinone

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Lipid A modification systems in gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Potent in vitro antibacterial activity of DS-8587, a novel broad-spectrum quinolone, against Acinetobacter baumannii

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Natural products--the future scaffolds for novel antibiotics?

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Natural products emergent

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Developing new antibacterials through natural product research

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Advances in the development of new tuberculosis drugs and treatment regimens

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Screening strategies to identify new antibiotics.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2013.86

7 January 2021

Identifiers

DOI

10.1038/JA.2013.86

1 reference

PubMed ID

24002361

Dimensions Publication ID

29 August 2017

0 references

1 reference

PubMed ID

24002361